Partners will develop formulations of VSEs™ and validate their ability to improve yields of adeno-associated vector (AAVs) at scale, lowering gene therapy costs at commercial scaleVirica and eXmoor ...
Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.76% ...
VSE Corp. shares were up 16% to $104.04 after the company priced its previously announced underwritten public offering of 1.7 million shares at $87 a share. The stock hit its 52-week high of $105.15 ...